This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Avidus Appoints Doug Ridley As CEO And Provides Corporate Update

VANCOUVER, BC and MESA, AZ, Jan. 14, 2014 /PRNewswire/ - Avidus Management Group Inc. ("Avidus" or the "Company") (TSXV: AVD) (OTC: ASNHF), today announced that it has appointed Doug Ridley as Chief Executive Officer and Director, effective January 15, 2014.  Mr. Ridley, who has a 25-year proven track record as a network marketing business leader and distributor, was appointed President of Avidus in June 2013 to develop and implement the company's strategic growth initiatives. Avidus is grateful to co-founder and outgoing CEO Daniel Lundell for his invaluable contributions to the company.  Mr. Lundell will remain as Chief Operating Officer and as Chairman of Avidus' board of Directors.  Mr. Lundell said, "We have worked very hard to get the company to this point and I am pleased to have Doug accept the appointment as CEO; his leadership has been and will be extremely valuable to the company.  Our shared vision for Avidus' future is exciting and I look forward to increased value for shareholders." Mr. Ridley has an accomplished career in this industry, having led another network marketing company, Quorum International, to more than $125 million annual sales in less than three years with $20 million in pre-tax profit.  As a successful distributor in the functional beverage space, he headed a network that generated more than $25 million in annual sales volume. Doug Ridley, President & CEO, commented: "I am excited to be appointed as CEO as we embark on fulfilling our vision of transforming Avidus into a premier company through strategic growth and acquisitions.  Since joining the company as President in June, I am pleased with the rapid progress we have made on several fronts.  In my 25-years in the industry, I have had the privilege of building successful businesses based on corporate culture and relationships, proven systems and quality products.  I feel that all of these elements are now in place as we enter 2014. The backbone of a successful network marketing business revolves around a professional and passionate team.  I was thrilled to have top network marketer Erik Cloud join Avidus as network leader in August, and results thus far have been very positive.  In Q4, recruitment was up 50% over Q3 and, in addition, we expanded our network's geographic reach.  In December, Steve and Linda Kampouroglou, extremely accomplished network marketing professionals based in Florida, joined Asantae and we anticipate that they will build upon their past successes.  They have most recently built network sales organizations in the tens of thousands representing tens of millions of dollars in sales per year. One of my initial goals for Asantae after joining the company was to create an exceptional product in the $25 billion US functional beverage space.  In October, we launched IS2™, a revolutionary inflammation and immune support nutritional beverage, which has been received very positively and quickly attracted network marketers from other well established companies.

Avidus enters the New Year with tremendous momentum and I believe we will experience significant growth in 2014.  We are currently evaluating a number of strategic acquisitions and anticipate completing our first transaction in the near term.  These businesses will not only add to our top and bottom line, but will also benefit and grow from our proven leadership, operational efficiencies and systems." About Avidus Avidus Management Group Inc. (TSX-V: AVD, OTC: ASNHF), through its wholly owned subsidiary, Asantae ( www.asantae.com) develops, produces and markets innovative nutritional products through direct and network marketing channels. The ingredients in Asantae's products have been shown to reduce chronic low-grade inflammation and oxidative stress, and support a healthy immune system that, according to scientific and medical research, are the underlying conditions for most modern epidemic diseases (diabetes, heart disease, obesity, stroke, etc.).  This news release may contain forward-looking statements relating to the Company's operations or to the environment in which it operates. Such statements are based on operations, estimates, forecasts and projections. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and may be beyond the Company's control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements, including those set forth in the Company's regulatory filings. In addition, such statements relate to the date on which they are made and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, save and except as may be required by applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Avidus Management Group Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs